To determine the role of activated BST-2 in cancer cells, we started by investigating the level of GRB2 – a docking protein that binds to phospho-tyrosine residues of activated receptors and recruits ERK1/2 to the signaling complex. The gene discussed is MAPK3; the disease is cancer.